Open

A Study of NX-1607 in Adults With Advanced Cancer

In this study, we want to learn more about the safety and tolerability of a drug called NX-1607 in adult patients with advanced tumors. We want to see if this new drug may be able to slow the growth of your cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will be asked how you are feeling and any changes in health since the previous visit. Throughout the study, safety assessments will be conducted to ensure your safety in the study.

Incentives

Gas and Travel Reimbursement

Total length of participation:
4 year or until disease progression

Looking for Specific Volunteers

Able to participate:

You have a confirmed tumor that is metastatic or unresectable
You have a tumor that can be biopsied with minimal risk
You have good organ and bone marrow function

Not eligible if:

You have active untreated brain metastases
You are not able to swallow pills
You were vaccinated with a live vaccine within 28 days
You are HIV positive
You have had major surgery within the past 4 weeks.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

22-2612

ClinicalTrials.gov

NCT05107674

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.